Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 9, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2025

Conditions

HER2-positive Gastric CancerImmunotherapy

Interventions

DRUG

Disitamab Vedotin combined with fruquintinib and Tislelizumab

Disitamab Vedotin 2.5mg/m2 ivgtt d1,15, fruquintinib 4mg qd po d1-21 and Tislelizumab 300mg ivgtt,q4w

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER